Last reviewed · How we verify

IPV control vaccine

Sinovac Biotech Co., Ltd · Phase 3 active Biologic

IPV (inactivated poliovirus vaccine) stimulates the immune system to produce antibodies against poliovirus types 1, 2, and 3, preventing poliomyelitis infection.

IPV (inactivated poliovirus vaccine) stimulates the immune system to produce antibodies against poliovirus types 1, 2, and 3, preventing poliomyelitis infection. Used for Poliomyelitis prevention in infants and children, Poliomyelitis prevention in adults (booster or primary series).

At a glance

Generic nameIPV control vaccine
SponsorSinovac Biotech Co., Ltd
Drug classvaccine
ModalityBiologic
Therapeutic areaImmunology
PhasePhase 3

Mechanism of action

The vaccine contains chemically inactivated poliovirus particles that trigger both humoral (antibody) and cellular immune responses without causing disease. This immunization provides protection against all three serotypes of poliovirus, preventing the virus from infecting motor neurons and causing paralysis. The inactivated formulation offers a safe alternative to live attenuated vaccines.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: